Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Two Novel Type 2 Oral Poliovirus Vaccine Candidates in Adults
NCT03430349Phase 1Completed
- Start
- May 2017
- Primary completion
- Sep 2017
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, single-blind trial of nOPV2 candidate 1 and novel oral poliovirus vaccine type 2 candidate 2 in poliomyelitis (2 arms). Primary endpoints: Number of Participants With Serious Adverse Events and Severe Adverse Events, Percentage of Participants With Viral Shedding and 3 more. Started May 2017; status: completed.
02
Drugs
nOPV2 candidate 1novel oral poliovirus vaccine type 2 candidate 2
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT03430349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03430349.